Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 504-509

  Linnemann, Birgit ^a   Schwonberg, Jan ^a   Toennes, Stefan W ^a   Mani, Helen ^a   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Aggregometry; Clopidogrel; HPLC coupled mass spectrometry; Non response; Peripheral arterial occlusive disease; Platelet reactivity

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CLOPIDOGREL CARBOXYLIC ACID; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION; TICLOPIDINE;

EID: 77949954528     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.039     Document Type: Article

References (36)

1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. CAPRIE Steering Committee.
2. Yusuf S., Zhao F., Mehta S.R., et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
3. Steinhubl S.R., Berger P.B., Mann J.T., et al. CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002, 288:2411-2420.
4. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006, 46:277-300.
5. Savi P., Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005, 31:174-183.
6. Gurbel P.A., Tantry U.S. Clopidogrel resistance?. Thromb Res 2007, 120:311-321.
7. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33:S1-S75.
8. Linnemann B., Schwonberg J., Mani H., Prochnow S., Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008, 6:677-683.
9. Mani H., Toennes S.W., Linnemann B., et al. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?. Ther Drug Monit 2008, 30:84-89.
10. Lainesse A., Ozalp Y., Wong H., Alpan R.S. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung 2004, 54:600-604.
11. McEwen J., Strauch G., Perles P., et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost 1999, 25(Suppl 2):47-50.
12. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008, 99:466-472.
13. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
14. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251.
15. Cassar K., Bachoo P., Ford I., Greaves M., Brittenden J. Variability in responsiveness to clopidogrel in patients with intermittend claudication. Eur J Vasc Endovasc Surg 2006, 32:71-75.
16. ® in peripheral angioplasty patients. Platelets 2002, 13:493-497.
17. ® be modified to detect P2Y12 inhibition?. J Thromb Haemost 2006, 4:1424-1426.
18. Gurbel P.A., BLiden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Circulation 2003, 107:2908-2913.
19. Gurbel P.A., Bliden K.P. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003, 91:1123-1125.
20. Harrison P., Segal H., Silver L., et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008, 19:119-124.
21. Schwartz K.A., Schwartz D.E., Ghosheh K., et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973-975.
22. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 2004, 147:293-300.
23. Siller-Matula J., Schroer K., Wojta J., Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007, 97:385-393.
24. Siller-Matula J.M., Lang I., Christ G., Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008, 52:1557-1563.
25. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260.
26. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48:1742-1750.
27. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
28. Frere C., Cuisset T., Quilici J., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007, 98:838-843.
29. Marcucci R., Paniccia R., Antonucci E., et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007, 98:844-851.
30. Samara W.M., Bliden K.P., Tantry U.S., Gurbel P.A. The difference between clopidogrel responsiveness and post-treatment platelet reactivity. Thromb Res 2005, 115:89-94.
31. Michelson A.D., Linden M.D., Furman M.I., et al. Evidence that pre-existent variability in platelet response to ADP accounts for clopidogrel resistance. J Thromb Haemost 2007, 5:75-81.
32. Aleil B., Ravanat C., Cazenave J.P., et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85-92.
33. Geiger J., Teichmann L., Grossmann R., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005, 51:957-965.
34. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results from the CREST study. J Am Coll Cardiol 2005, 46:1827-1832.
35. Barragan P., Bouvier J.L., Roquebert P.O., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphorylation. Catheter Cardiovasc Interv 2003, 59:295-302.
36. Angiolillo D.J., Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 2007, 98:707-709.